Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR) -- Ignore unavailable to you. Want to Upgrade?

To: Rob-Chemist who wrote (287)	5/28/1998 8:56:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 328

Hi Rob: Generally, can you be more specific? >>I would not be surprised if a large number of other drug companies also license the SELEX technology for target validation, thereby providing NXTR with a significant influx of cash. << What cash? Under what condition? With another dilution at $10/share!!!!! >>I think that it is significant that they did not sell the rights to using the SELEX either for the development of new drugs or diagnostics.<< They will love to sell SELEX's aptamers, if anyone is willing to bay this crapshot! Know anyone? >>Finally, this may be the start of a larger collaboration between Glaxo-Wellcome and NXTR. A few years ago, Burrows-Wellcome (prior to the merger with Glaxo) was very interested in the diagnostic aspects of SELEX. NXTR, however, decided to collaborate with other companies at the time.<< Maybe? But, I have serious doubt that this interest is in SELEX itself. Contrary, lurtotecan has significant bad points, so to be able to bring drug on market Gloxo find NXTR to do job for them, if it work at all. Instead paying big bucks to NXTR (ask SEQU what they got from Bayer after licensing DEG technology for cyprofloxacin lipo formulation, and Bayer will develop manufacturing process itself and pay all clinical expense), they for free licensed SELEX (where maybe is some advantage for target validation) and invested in NXTR at huge discount price. Let me put record strait. At current price NXTR is minimum ~60% undervalued, based solely on AmBisome. Why????? I have funny filling that someone (and this SOMEONE is NXTR and PW) is intentionally keeping stock undervalued. Why, you figure for yourself. This are my 0.02 cents. Miljenko